Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 6;12:5262. doi: 10.1038/s41467-021-25618-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — A Clinical features and molecular data for 53 tumors (rows) are displayed as heatmaps. Each column represents an individual tumor. Patients were separated into eight groups: those with ASPSCR1-TFE3 (n = 8), with SFPQ-TFE3 (n = 13), with NONO-TFE3 (n = 8), with MED15-TFE3 (n = 8), with PRCC-TFE3 (n = 4), with RBM10-TFE3 fusions (n = 4), with rare TFE3-associated gene fusions (n = 3, including FUBP1-TFE3, SETD1B-TFE3, and ZC3H4-TFE3) and unknow partners (n = 5). The top panel shows fusion partners. The middle panel shows clinical features, including gender, age, tumor size, TNM stage, ISUP, survival status, SCNA, and SCNA burden. Each subsequent panel displays a specific molecular profile: number of mutations and the fraction of each COSMIC signature in the genome. B Frequently mutated genes in the TFE3-tRCC cohort. The red dashed line denotes three mutated patients. Tumor suppresser genes are labeled with bold font. C Focal amplification and deletion determined from GISTIC 2.0 analysis. The green line indicates the cut-off for significance (q = 0.25). P values significantly peaks were identified at FDR q value <0.25. The top and bottom numerical values refer to G-scores and q values, respectively. D Kaplan–Meier curves show the OS between the patients with 22p loss and 22p normal. P value was determined by two-sided log-rank test. TFE3-tRCC TFE3-translocation renal cell carcinoma, ISUP International Society of Urological Pathology, SCNA somatic copy number alteration, OS overall survival.